Recent investigations have focused on the intersection of GLP|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GIP activators are increasingly employed for addressing type 2 diabetes mellitus, their potential consequences on reinforcement circuits, specifically influenced by dopamine networks, are receiving significant inte